Tenax Therapeutics faces securities class action deadline on December 28, 2026

A securities class action has been filed against Tenax Therapeutics (TENX) alleging the company overstated the regulatory and commercial prospects of its lead drug TNX-103 before the Phase 3 LEVEL trial missed its primary endpoint. The stock fell 89.77% in a single session. The lead plaintiff deadline is December 28, 2026.